A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Res
Autors principals: Du, Xuexiang, Tang, Fei, Liu, Mingyue, Su, Juanjuan, Zhang, Yan, Wu, Wei, Devenport, Martin, Lazarski, Christopher A, Zhang, Peng, Wang, Xu, Ye, Peiying, Wang, Changyu, Hwang, Eugene, Zhu, Tinghui, Xu, Ting, Zheng, Pan, Liu, Yang
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5939050/
https://ncbi.nlm.nih.gov/pubmed/29472691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-018-0011-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars